Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from PharmaTher Holdings Ltd ( (TSE:PHRM) ).
PharmaTher Holdings Ltd. is advancing its Phase 3 FDA package for the use of ketamine in treating levodopa-induced dyskinesia in Parkinson’s disease. The company is preparing for a meeting with the FDA to align on a single, well-controlled Phase 3 study under the 505(b)(2) pathway. This strategic move aims to leverage existing clinical evidence and intellectual property, with the potential to tap into a significant market opportunity estimated at US$0.75-$2.2 billion. The company is also in discussions with potential partners for co-development and licensing, which could accelerate timelines and optimize commercial reach.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine.
Average Trading Volume: 368,103
Technical Sentiment Signal: Sell
Current Market Cap: C$13.28M
For a thorough assessment of PHRM stock, go to TipRanks’ Stock Analysis page.